24 September 2019 | News
AbbVie will present 20 additional abstracts featuring new and updated data of investigational medicines, and DUODOPA, in Parkinson's disease and other neurodegenerative disorders
AbbVie , a research-based global biopharmaceutical company, has announced experts in the neuroscience field will present results from two late-breaking abstracts, including final data from the Phase 1b study evaluating the safety and tolerability of the investigational medicine ABBV-951 in patients with advanced Parkinson's disease (PD), and data from the real-world DUOGLOBE study, evaluating the effect of DUODOPA® (levodopa/carbidopa intestinal gel) in patients with advanced Parkinson's disease. In total, 22 abstracts featuring new and updated data evaluating AbbVie's neuroscience portfolio and pipeline will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders®, September 22-26 in Nice, France.
The Phase 1b study evaluating ABBV-951 was designed to determine the safety and tolerability of ABBV-951, an investigational solution of levodopa/carbidopa delivered through continuous subcutaneous infusion (CSCI) in patients with advanced Parkinson's disease. A Phase 3 study evaluating the safety and tolerability of ABBV-951 (NCT-03781167) CSCI over 24 hours per day is currently enrolling patients. The design of the Phase 3 study will be presented as a poster at the congress.
The multinational, real-world observational study, DUOGLOBE, was designed to evaluate the effect of DUODOPA on motor symptoms/motor complications (including "off" time and dyskinesia), quality of life (QoL) and caregiver burden, in patients with advanced PD who were treated with DUODOPA in routine clinical practice. Duodopa is indicated for the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.
"Our research presented at the congress demonstrates our longstanding commitment to developing and delivering science that will make a difference in the lives of people with Parkinson's disease and other neurodegenerative conditions," said Michael Gold, M.D., vice president, neuroscience development, AbbVie. "We are excited to share this latest data with leading researchers around the world as we take a few steps closer to potentially providing patients with much needed additional treatment options."
Other data presentations include the pharmacokinetics of ABBV-951, the impact of progressive supranuclear palsy (PSP) on healthcare resource utilization and PSP caregivers, and several studies examining DUODOPA in advanced PD patients in a variety of clinical and real-world settings, including its impact on motor symptoms when using wearable sensors, its utilization in patients being treated with add-on therapies, and in patients with non-motor symptoms. Abstracts demonstrating the prevalence, impact and burden of PD will also be presented.